⟵ Back to Search Results

BGB-900-105 AdvanTIG-105

Recruiting

Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors

Beigene Study ID info

BGB-900-105 AdvanTIG-105

ClinicalTrials.gov ID info

NCT04047862

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents

Locations

Study Overview

Sex: All

Age: 18 Years and older   (Adult, Older Adult)

No Study Documents